JSB Market Research: Myasthenia Gravis - Pipeline Review, H2 2014

Myasthenia Gravis - Pipeline Review, H2 2014 

On 17 th December 2014 

Summary 

Myasthenia Gravis - Pipeline Review, H2 2014, provides an overview of the Myasthenia Graviss 

therapeutic pipeline. 

This report provides comprehensive information on the therapeutic development for 

Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics 

assessment by drug target, mechanism of action (MoA), route of administration (RoA) and 

molecule type, along with latest updates, and featured news and press releases. It also reviews 

key players involved in the therapeutic development for Myasthenia Gravis and special features 

on late-stage and discontinued projects. 

Global Markets Directs report features investigational drugs from across globe covering over 20 

therapy areas and nearly 3,000 indications. The report is built using data and information 

sourced from Global Markets Directs proprietary databases, Company/University websites, SEC 

filings, investor presentations and featured press releases from company/university sites and 

industry-specific third party sources, put together by Global Markets Directs team. Drug 

profiles/records featured in the report undergoes periodic updation following a stringent set of 

processes that ensures that all the profiles are updated with the latest set of information. 

Email ID- contact@jsbmarketresearch.com 

Tel No- 91 2241236650 

Published by- http:/www.jsbmarketresearch.com/

Additionally, processes including live news & deals tracking, browser based alert-box and 

clinical trials registries tracking ensure that the most recent developments are captured on a 

real time basis. 

The report enhances decision making capabilities and help to create effective counter strategies 

to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and 

MOAs to produce first-in-class and best-in-class products. 

Note*: Certain sections in the report may be removed or altered based on the availability and 

relevance of data for the indicated disease. 

You can buy this Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-myastheniagravis-pipeline-review-h2-2014-146094 

Scope 

- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis 

- The report reviews key pipeline products under drug profile section which includes, product 

description, MoA and R&D brief, licensing and collaboration details & other developmental 

activities 

- The report reviews key players involved in the therapeutics development for Myasthenia 

Gravis and enlists all their major and minor projects 

- The report summarizes all the dormant and discontinued pipeline projects 

- A review of the Myasthenia Gravis products under development by companies and 

universities/research institutes based on information derived from company and industryspecific 

sources 

- Pipeline products coverage based on various stages of development ranging from preregistration 

till discovery and undisclosed stages 

- A detailed assessment of monotherapy and combination therapy pipeline projects 

- Coverage of the Myasthenia Gravis pipeline on the basis of target, MoA, route of 

administration and molecule type 


Tel No- 91 2241236650 


- Latest news and deals relating related to pipeline products 

Reasons to buy 

- Provides strategically significant competitor information, analysis, and insights to formulate 

effective R&D development strategies 

- Identify emerging players with potentially strong product portfolio and create effective 

counter-strategies to gain competitive advantage 

- Develop strategic initiatives by understanding the focus areas of leading companies 

- Identify and understand important and diverse types of therapeutics under development for 

Myasthenia Gravis 

- Plan mergers and acquisitions effectively by identifying key players of the most promising 

pipeline 

- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline 

depth and focus of Indication therapeutics 

- Develop and design in-licensing and out-licensing strategies by identifying prospective 

partners with the most attractive projects to enhance and expand business potential and Scope 

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the 

factors that drove them from pipeline 

Other industries we cover: 

 

 

 

 

 

 

 

 

 

Advertising and Media 

Automotive and Parts 

Consumer Goods 

Healthcare and Medical 

Finance and Banking 

Food and Beverages 

Travel and Tourism 

Textiles and Clothing 

SWOT Analysis 


Tel No- 91 2241236650 


Discounts on Market Research Reports till 31st December, 2014 

For more inquiries, contact at +91 - 998 729 5242 / 

contact@jsbmarketresearch.com 

Table of Content 

Myasthenia Gravis Overview 8 

Therapeutics Development 9 

Pipeline Products for Myasthenia Gravis - Overview 9 

Pipeline Products for Myasthenia Gravis - Comparative Analysis 10 

Myasthenia Gravis - Therapeutics under Development by Companies 11 

Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes 13 

Myasthenia Gravis - Pipeline Products Glance 14 

Late Stage Products 14 

Clinical Stage Products 15 

Early Stage Products 16 

Myasthenia Gravis - Products under Development by Companies 17 

Myasthenia Gravis - Products under Investigation by Universities/Institutes 18 

Myasthenia Gravis - Companies Involved in Therapeutics Development 19 

Alexion Pharmaceuticals, Inc. 19 


Tel No- 91 2241236650 


Alnylam Pharmaceuticals, Inc. 20 

Astellas Pharma Inc. 21 

Biokine Therapeutics Ltd. 22 

CuraVac, Inc. 23 

Cytokinetics, Inc. 24 

GlaxoSmithKline plc 25 

Grifols, S.A. 26 

HanAll Biopharma Co., Ltd. 27 

Neurotune AG 28 

Pfizer Inc. 29 

Regenesance BV 30 

Toleranzia AB 31 

Myasthenia Gravis - Therapeutics Assessment 32 

Assessment by Monotherapy Products 32 

Assessment by Target 33 

Assessment by Mechanism of Action 35 

Assessment by Route of Administration 37 

Assessment by Molecule Type 39 

Drug Profiles 41 

ALN-CC5 - Drug Profile 41 


Tel No- 91 2241236650 


Product Description 41 

Mechanism of Action 41 

R&D Progress 41 

belimumab - Drug Profile 42 




BKT-130 - Drug Profile 45 




CK-2066260 - Drug Profile 46 




eculizumab - Drug Profile 47 




GL-2045 - Drug Profile 50 


Tel No- 91 2241236650 





HL-161 - Drug Profile 51 




immune globulin (human) - Drug Profile 52 




NT-1654 - Drug Profile 54 




Recombinant Coversin - Drug Profile 55 




Recombinant Protein for Myasthenia Gravis - Drug Profile 56 


Tel No- 91 2241236650 





Regenemab - Drug Profile 57 




tacrolimus - Drug Profile 58 




tirasemtiv - Drug Profile 59 




Vaccine for Myasthenia Gravis - Drug Profile 62 




Vaccine for Myasthenia Gravis - Drug Profile 63 


Tel No- 91 2241236650 





Myasthenia Gravis - Recent Pipeline Updates 64 

Myasthenia Gravis - Dormant Projects 79 

Myasthenia Gravis - Discontinued Products 80 

Myasthenia Gravis - Product Development Milestones 81 

Featured News & Press Releases 81 

Sep 16, 2014: Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously 

Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the 

Treatment of Complement-Mediated Diseases 81 

Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for 

the Treatment of Patients with Myasthenia Gravis (MG) 82 

Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of 

Patients with Myasthenia Gravis 83 

Jun 09, 2014: Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN- 

CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 

in Development for the Treatment of Complement-Mediated Diseases 83 

Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential 

Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized 

Myasthenia Gravis 85 

Apr 24, 2014: Toleranzia supported by VINNOVA 86 

Dec 08, 2013: New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting 

Complement Component C5 for the Treatment of Complement-Mediated Diseases, 

Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in 

Non-Human Primates 86 


Tel No- 91 2241236650 


Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of 

Complement-mediated Diseases 89 

Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of 

Tirasemtiv In Patients With Myasthenia Gravis 90 

Mar 13, 2013: Cytokinetics Announces Presentation Of Phase IIa Trial Data On Tirasemtiv At 

65th AAN Annual Meeting 91 

Appendix 92 

Methodology 92 

Coverage 92 

Secondary Research 92 

Primary Research 92 

Expert Panel Validation 92 

Contact Us 93 

Disclaimer 93 

List Of Tables 

Number of Products under Development for Myasthenia Gravis, H2 2014 9 

Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 

2014 10 

Number of Products under Development by Companies, H2 2014 12 

Number of Products under Investigation by Universities/Institutes, H2 2014 13 

Comparative Analysis by Late Stage Development, H2 2014 14 

Comparative Analysis by Clinical Stage Development, H2 2014 15 


Tel No- 91 2241236650 


Comparative Analysis by Early Stage Development, H2 2014 16 

Products under Development by Companies, H2 2014 17 

Products under Investigation by Universities/Institutes, H2 2014 18 

Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2014 19 

Myasthenia Gravis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 20 

Myasthenia Gravis - Pipeline by Astellas Pharma Inc., H2 2014 21 

Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H2 2014 22 

Myasthenia Gravis - Pipeline by CuraVac, Inc., H2 2014 23 

Myasthenia Gravis - Pipeline by Cytokinetics, Inc., H2 2014 24 

Myasthenia Gravis - Pipeline by GlaxoSmithKline plc, H2 2014 25 

Myasthenia Gravis - Pipeline by Grifols, S.A., H2 2014 26 

Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 27 

Myasthenia Gravis - Pipeline by Neurotune AG, H2 2014 28 

Myasthenia Gravis - Pipeline by Pfizer Inc., H2 2014 29 

Myasthenia Gravis - Pipeline by Regenesance BV, H2 2014 30 

Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2014 31 

Assessment by Monotherapy Products, H2 2014 32 

Number of Products by Stage and Target, H2 2014 34 

Number of Products by Stage and Mechanism of Action, H2 2014 36 

Number of Products by Stage and Route of Administration, H2 2014 38 


Tel No- 91 2241236650 


Number of Products by Stage and Molecule Type, H2 2014 40 

Myasthenia Gravis Therapeutics - Recent Pipeline Updates, H2 2014 64 

Myasthenia Gravis - Dormant Projects, H2 2014 79 

Myasthenia Gravis - Discontinued Products, H2 2014 80 

List Of Figures 

Number of Products under Development for Myasthenia Gravis, H2 2014 9 

Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 

2014 10 

Number of Products under Development by Companies, H2 2014 11 

Comparative Analysis by Clinical Stage Development, H2 2014 15 

Comparative Analysis by Early Stage Products, H2 2014 16 

Assessment by Monotherapy Products, H2 2014 32 

Number of Products by Top 10 Targets, H2 2014 33 

Number of Products by Stage and Top 10 Targets, H2 2014 34 

Number of Products by Top 10 Mechanism of Actions, H2 2014 35 

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 36 

Number of Products by Top 10 Routes of Administration, H2 2014 37 

Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38 

Number of Products by Top 10 Molecule Types, H2 2014 39 


Tel No- 91 2241236650 


Number of Products by Stage and Top 10 Molecule Types, H2 2014 40 

Report Price: 

Licence Type 

Price 

PDF $ 2000 

Site License $ 4000 

Enterprise Wide Licence $ 6000 

Related Reports: 

Community-Acquired Infections Global Clinical Trials Review, H2, 2014 

Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014 

Hemorrhagic Fever Global Clinical Trials Review, H2, 2014 

Apnea Global Clinical Trials Review, H2, 2014 

Hepatitis D Global Clinical Trials Review, H2, 2014 

Herpes Infections Global Clinical Trials Review, H2, 2014 

HIV-1 Infection Global Clinical Trials Review, H2, 2014 

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014 

Metastatic Breast Cancer - Pipeline Review, H2 2014 

Anthrax - Pipeline Review, H2 2014 

You can order this report by calling on +91 - 998 7295 242 or mail us 

your contact details at contact@jsbmarketresearch.com 


Tel No- 91 2241236650 


About JSB Market Research:- 

JSB market research is a leading player in the market of research report distribution. It is onestop-shop 

for all information related to market research for any sector of the industry. Along 

with providing in-depth analysis though reports, JSB market research also provides regular 

updates of the market though newsletters. Our reports are a well-researched work of market 

researchers with an extensive knowledge and a good level of market experience. 

To know more on Myasthenia Gravis - Pipeline Review, H2 2014 

http://www.jsbmarketresearch.com/healthcare-medical/r-myasthenia-gravispipeline-review-h2-2014-146094 


Tel No- 91 2241236650

JSB Market Research: Myasthenia Gravis - Pipeline Review, H2 2014

Create successful ePaper yourself

Delete template?

Save as template?